BioCentury | Sep 19, 2011
Company News

Physiomics, ValiRx deal

Physiomics will use its Virtual Tumour model technology to predict the ideal treatment regimens of VAL201 from ValiRx's ValiPharma Ltd. subsidiary for Phase I testing. Physiomics will not receive an upfront payment but will be...
BioCentury | Mar 22, 2010
Company News

Physiomics, Sareum deal

Physiomics will use its SystemCell in silico technology to simulate the effects of cancer drugs in living systems with an undisclosed compound from Sareum's checkpoint kinase 1 (Chk1) inhibitor program in combination with Gemzar gemcitabine...
BioCentury | Dec 24, 2007
Company News

Physiomics, ValiRx deal

VAL and PYC completed the first part of a February deal to use PYC's in silico simulations of cellular processes to select cancer targets for VAL's GeneICE oligonucleotide-protein fusion molecules that suppress gene expression. The...
BioCentury | Feb 5, 2007
Finance

AIM iceberg

AIM iceberg Company Date Raised Post-$ Mcap 12/29/06 Chg York Pharma (LSE:YRK) 4/16/04 £1.0 £2.3 £23.2 932% Lipoxen (LSE:LPX) 1/17/06 £3.8 £13.1 £35.4 169% Vectura (LSE:VEC) 6/25/04 £20.0 £60.0 £156.8 161% ReNeuron (LSE:RENE) 8/5/05 £9.5...
BioCentury | Apr 10, 2006
Company News

Physiomics board of directors update

Physiomics plc (LSE:PYC), Oxford, U.K. Business: Computational chemistry/biology Appointed: David Evans, former deputy managing director of Axis-Shield plc, as chairman WIR Staff...
BioCentury | Jun 27, 2005
Company News

Physiomics, Bayer sales and marketing update

BAYG's Bayer Technology Services GmbH subsidiary granted PYC U.K. distribution rights to PK-Sim pharmacokinetic modeling products and services. Physiomics plc (LSE:PYC), Oxford, U.K. Bayer AG (FSE:BAYG; BAY), Leverkusen, Germany Business: Bioinformatics WIR Staff...
BioCentury | May 16, 2005
Finance

Comparing IPO performance

Comparing IPO performance Company Date Raised Post-IPO valuation 5/13 Mcap % chg bioMerieux (Euronext:BIM) 7/8/04 $29.5 $1,416.7 $1,758.0 24% Eyetech (EYET) 1/29/04 $157.0 $831.6 $981.2 18% Theravance (THRX) 10/5/04 $98.4 $817.6 $909.9 11% Idenix (IDIX)...
BioCentury | Apr 18, 2005
Finance

AIM IPO performance

AIM IPO performance Company Date Raised Post-IPO valuation 4/15 Mcap Chg Allergy Therap (LSE:AGY) 10/6/04 $28.8 $83.0 $142.5 72% Evolutec Group (LSE:EVC) 7/21/04 $10.6 $23.9 $51.5 116% Physiomics (LSE:PYC) 12/20/04 $1.5 $9.2 $7.6 -18% Plethora...
BioCentury | Apr 4, 2005
Finance

European IPO performance

European IPO performance Company Date Raised Post-IPO valuation 3/31 mcap Chg Major market IPOs Ardana (LSE:ARA) 3/4/05 $40.3 $136.7 $126.2 -8% Ark (LSE:AKT) 3/3/04 $103.2 $314.3 $258.4 -18% Basilea (SWX:BSLN) 3/25/04 $162.3 $571.8 $552.0 -3%...
BioCentury | Jan 3, 2005
Finance

European IPO performance

European IPO performance Company Date Price Mcap 12/31 cls 12/31 mcap % chg Main market IPOs Ark (LSE:AKT) 3/3/04 133p £168.3 ($314.3) 85.00p £106.9 ($205.7) -36% Basilea (SWX:BSLN) 3/25/04 CHF 98 CHF 725.2 ($571.8) CHF...
Items per page:
1 - 10 of 60
BioCentury | Sep 19, 2011
Company News

Physiomics, ValiRx deal

Physiomics will use its Virtual Tumour model technology to predict the ideal treatment regimens of VAL201 from ValiRx's ValiPharma Ltd. subsidiary for Phase I testing. Physiomics will not receive an upfront payment but will be...
BioCentury | Mar 22, 2010
Company News

Physiomics, Sareum deal

Physiomics will use its SystemCell in silico technology to simulate the effects of cancer drugs in living systems with an undisclosed compound from Sareum's checkpoint kinase 1 (Chk1) inhibitor program in combination with Gemzar gemcitabine...
BioCentury | Dec 24, 2007
Company News

Physiomics, ValiRx deal

VAL and PYC completed the first part of a February deal to use PYC's in silico simulations of cellular processes to select cancer targets for VAL's GeneICE oligonucleotide-protein fusion molecules that suppress gene expression. The...
BioCentury | Feb 5, 2007
Finance

AIM iceberg

AIM iceberg Company Date Raised Post-$ Mcap 12/29/06 Chg York Pharma (LSE:YRK) 4/16/04 £1.0 £2.3 £23.2 932% Lipoxen (LSE:LPX) 1/17/06 £3.8 £13.1 £35.4 169% Vectura (LSE:VEC) 6/25/04 £20.0 £60.0 £156.8 161% ReNeuron (LSE:RENE) 8/5/05 £9.5...
BioCentury | Apr 10, 2006
Company News

Physiomics board of directors update

Physiomics plc (LSE:PYC), Oxford, U.K. Business: Computational chemistry/biology Appointed: David Evans, former deputy managing director of Axis-Shield plc, as chairman WIR Staff...
BioCentury | Jun 27, 2005
Company News

Physiomics, Bayer sales and marketing update

BAYG's Bayer Technology Services GmbH subsidiary granted PYC U.K. distribution rights to PK-Sim pharmacokinetic modeling products and services. Physiomics plc (LSE:PYC), Oxford, U.K. Bayer AG (FSE:BAYG; BAY), Leverkusen, Germany Business: Bioinformatics WIR Staff...
BioCentury | May 16, 2005
Finance

Comparing IPO performance

Comparing IPO performance Company Date Raised Post-IPO valuation 5/13 Mcap % chg bioMerieux (Euronext:BIM) 7/8/04 $29.5 $1,416.7 $1,758.0 24% Eyetech (EYET) 1/29/04 $157.0 $831.6 $981.2 18% Theravance (THRX) 10/5/04 $98.4 $817.6 $909.9 11% Idenix (IDIX)...
BioCentury | Apr 18, 2005
Finance

AIM IPO performance

AIM IPO performance Company Date Raised Post-IPO valuation 4/15 Mcap Chg Allergy Therap (LSE:AGY) 10/6/04 $28.8 $83.0 $142.5 72% Evolutec Group (LSE:EVC) 7/21/04 $10.6 $23.9 $51.5 116% Physiomics (LSE:PYC) 12/20/04 $1.5 $9.2 $7.6 -18% Plethora...
BioCentury | Apr 4, 2005
Finance

European IPO performance

European IPO performance Company Date Raised Post-IPO valuation 3/31 mcap Chg Major market IPOs Ardana (LSE:ARA) 3/4/05 $40.3 $136.7 $126.2 -8% Ark (LSE:AKT) 3/3/04 $103.2 $314.3 $258.4 -18% Basilea (SWX:BSLN) 3/25/04 $162.3 $571.8 $552.0 -3%...
BioCentury | Jan 3, 2005
Finance

European IPO performance

European IPO performance Company Date Price Mcap 12/31 cls 12/31 mcap % chg Main market IPOs Ark (LSE:AKT) 3/3/04 133p £168.3 ($314.3) 85.00p £106.9 ($205.7) -36% Basilea (SWX:BSLN) 3/25/04 CHF 98 CHF 725.2 ($571.8) CHF...
Items per page:
1 - 10 of 60